Somatic mutations and current and future targeted therapies
| Mutation . | Drug . |
|---|---|
| Flt3 | Crenolanib and quizartinib |
| IDH1 | AG-120 |
| IDH2 | AG-221 |
| UTX | EZH2 inhibitor |
| Heterozygous TET2 | 5-azacytidine/vitamin C? |
| DNMT3A | S-adenosylmethionine? |
| JAK2 | Ruxolitinib |
| cKIT | Axitinib and dasatinib |
| Del 5q | Lenalidomide |
| Spliceosomal factor | H3B-8800? |
| CSF3R | Ruxolitinib |
| Mutation . | Drug . |
|---|---|
| Flt3 | Crenolanib and quizartinib |
| IDH1 | AG-120 |
| IDH2 | AG-221 |
| UTX | EZH2 inhibitor |
| Heterozygous TET2 | 5-azacytidine/vitamin C? |
| DNMT3A | S-adenosylmethionine? |
| JAK2 | Ruxolitinib |
| cKIT | Axitinib and dasatinib |
| Del 5q | Lenalidomide |
| Spliceosomal factor | H3B-8800? |
| CSF3R | Ruxolitinib |
?, future potential.